CIJI BOUTIAN: Open Payments
NPI 1861254542 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,469 in 45 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $434 · 2025 $2,469
Food & beverage: $2,469
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 21 | $1,085 |
| Gilead Sciences, Inc. | 13 | $581 |
| Ipsen Biopharmaceuticals, Inc | 5 | $168 |
| Medtronic, Inc. | 1 | $151 |
| Novo Nordisk Inc | 2 | $148 |
| AstraZeneca Pharmaceuticals LP | 1 | $118 |
| Mirum Pharmaceuticals, Inc. | 1 | $114 |
| Intercept Pharmaceuticals, Inc. | 1 | $104 |
Products named: REZDIFFRA, INTERSTIM, Wegovy, Epclusa, Bylvay, TEZSPIRE, Livmarli, OCALIVA.
Industry payments across LA — which companies pay providers there.
